Pacific Sage Partners LLC Cuts Stock Holdings in Eli Lilly and Company $LLY

Pacific Sage Partners LLC cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 1.6% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 1,374 shares of the company’s stock after selling 23 shares during the period. Pacific Sage Partners LLC’s holdings in Eli Lilly and Company were worth $1,071,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in LLY. WestEnd Advisors LLC raised its holdings in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after buying an additional 21 shares during the period. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the first quarter worth $27,000. Citizens National Bank Trust Department increased its position in shares of Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new position in shares of Eli Lilly and Company in the 1st quarter valued at $40,000. Finally, Mascagni Wealth Management Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at $43,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 3.8%

LLY stock opened at $713.87 on Friday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a 50 day simple moving average of $735.09 and a 200-day simple moving average of $767.88. The company has a market capitalization of $675.65 billion, a P/E ratio of 46.66, a PEG ratio of 1.03 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jamere Jackson acquired 200 shares of the stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on LLY. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Guggenheim lowered their target price on Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating for the company in a research note on Wednesday, August 13th. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Cantor Fitzgerald lowered their price objective on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research report on Wednesday, August 13th. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.